32 related articles for article (PubMed ID: 21897294)
1. Renin-Angiotensin System Blockade Is Associated with Exercise Capacity, Sympathetic Activity, and Endothelial Function in Patients with Chronic Kidney Disease.
Jeong JH; Sprick JD; DaCosta D; Quyyumi AA; Park J
Kidney Blood Press Res; 2022; 47(2):103-112. PubMed ID: 34758473
[TBL] [Abstract][Full Text] [Related]
2. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Tunnicliffe DJ; Palmer SC; Cashmore BA; Saglimbene VM; Krishnasamy R; Lambert K; Johnson DW; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD007784. PubMed ID: 38018702
[TBL] [Abstract][Full Text] [Related]
3. Clarification of hypertension mechanisms provided by the research of central circulatory regulation.
Kishi T
Hypertens Res; 2023 Aug; 46(8):1908-1916. PubMed ID: 37277436
[TBL] [Abstract][Full Text] [Related]
4. Autonomic cardiovascular alterations as therapeutic targets in chronic kidney disease.
Seravalle G; Quarti-Trevano F; Vanoli J; Lovati C; Grassi G
Clin Auton Res; 2021 Aug; 31(4):491-498. PubMed ID: 33606138
[TBL] [Abstract][Full Text] [Related]
5. Sympathetic Overactivity in Chronic Kidney Disease: Consequences and Mechanisms.
Kaur J; Young BE; Fadel PJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28767097
[TBL] [Abstract][Full Text] [Related]
6. The effect of statins on sympathetic activity: a meta-analysis.
Lewandowski J; Symonides B; Gaciong Z; Siński M
Clin Auton Res; 2015 Apr; 25(2):125-31. PubMed ID: 25739473
[TBL] [Abstract][Full Text] [Related]
7. Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Azushima K; Uneda K; Tamura K; Wakui H; Ohsawa M; Kobayashi R; Dejima T; Kanaoka T; Maeda A; Toya Y; Umemura S
Biomed Res Int; 2014; 2014():437087. PubMed ID: 24809050
[TBL] [Abstract][Full Text] [Related]
8. Statin improves flow-mediated vasodilation in chronic kidney diseases.
Takenaka T; Takane H; Kikuta T; Watanabe Y; Suzuki H
Int J Hypertens; 2013; 2013():876865. PubMed ID: 24396591
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin in the autonomic system is dependent on the increased gain/sensitivity of the baroreceptors.
Moreira ED; Mostarda CT; Moraes-Silva IC; Ferreira JB; Dos Santos F; Lacchini S; De Angelis K; Rodrigues B; Irigoyen MC
Physiol Rep; 2013 Aug; 1(3):e00045. PubMed ID: 24303130
[TBL] [Abstract][Full Text] [Related]
10. The sympathetic nervous system in chronic kidney disease.
Ewen S; Ukena C; Linz D; Schmieder RE; Böhm M; Mahfoud F
Curr Hypertens Rep; 2013 Aug; 15(4):370-6. PubMed ID: 23737218
[TBL] [Abstract][Full Text] [Related]
11. Sympathetic hyperactivity in chronic kidney disease: pathophysiology and (new) treatment options.
Vink EE; de Jager RL; Blankestijn PJ
Curr Hypertens Rep; 2013 Apr; 15(2):95-101. PubMed ID: 23354877
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in the brain causes hypertension via sympathoexcitation.
Kishi T; Hirooka Y
Front Physiol; 2012; 3():335. PubMed ID: 22934082
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk in chronic kidney disease: role of the sympathetic nervous system.
Park J
Cardiol Res Pract; 2012; 2012():319432. PubMed ID: 22919537
[TBL] [Abstract][Full Text] [Related]
14. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure.
Deo SH; Fisher JP; Vianna LC; Kim A; Chockalingam A; Zimmerman MC; Zucker IH; Fadel PJ
Am J Physiol Heart Circ Physiol; 2012 Aug; 303(3):H377-85. PubMed ID: 22661508
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.
Siddiqi L; Joles JA; Oey PL; Blankestijn PJ
J Hypertens; 2011 Nov; 29(11):2176-80. PubMed ID: 21897294
[TBL] [Abstract][Full Text] [Related]
16. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients.
Siddiqi L; Oey PL; Blankestijn PJ
Nephrol Dial Transplant; 2011 Sep; 26(9):2930-4. PubMed ID: 21467128
[TBL] [Abstract][Full Text] [Related]
17. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment.
Penne EL; Neumann J; Klein IH; Oey PL; Bots ML; Blankestijn PJ
J Nephrol; 2009; 22(2):208-15. PubMed ID: 19384838
[TBL] [Abstract][Full Text] [Related]
18. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hypertension in chronic kidney disease.
Toto RD
Semin Nephrol; 2005 Nov; 25(6):435-9. PubMed ID: 16298269
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
